Report cover image

U.S. Dural Sealants And Fibrin Glues Market Size, Share & Trends Analysis Report By CPT Procedure Code (61510 / 61512, 61320 - 61323, 61518, 62140 / 62141, 63707, 63709, 63710), By End Use, And Segment Forecasts, 2025 - 2035

Published Nov 17, 2025
Length 125 Pages
SKU # GV20649611

Description

Market Size & Trends

The U.S. dural sealants and fibrin glues market size was valued at USD 6.57 billion in 2024 and is expected to reach USD 10.99 billion by 2035, growing at a CAGR of 4.78% from 2025 to 2035. Growth is driven by increasing neurosurgical and spinal procedure volumes, particularly complex cranial, posterior fossa, and spinal duraplasty cases where cerebrospinal fluid (CSF) leak prevention is critical.

According to a 2024 study published in the Journal of Neurosurgery: Spine by Dykhouse et al., spine procedure volumes in the U.S. increased from approximately 800,000 in 2013 to over 1.1 million in 2022, representing a steady and sustained growth. This expansion is closely linked with a surge in degenerative spine disorders, aging demographics, and improved surgical safety, particularly for older patients.

Hospitals and ambulatory surgical centers prioritize sealants and glues that ensure watertight closure, reduce postoperative complications, and support value-based outcomes. The rising adoption of advanced products, such as PEG-based hydrogels, collagen grafts, and synthetic sealants, along with favorable reimbursement and increasing outpatient surgical volumes, further fuels market expansion. Hospitals and surgical centers are prioritizing products that minimize cerebrospinal fluid (CSF) leaks, shorten recovery times, and lower readmission rates. According to the Agency for Healthcare Research and Quality (AHRQ), postoperative CSF leaks account for up to 3-8% of neurosurgical complications, often requiring revision surgery. These reoperations not only elevate costs by nearly USD 25,000-USD 40,000 per case, but also significantly extend hospital stays and increase infection risk.

Moreover, the accelerating adoption of robotic-assisted and image-guided surgery (IGS) presents a clear growth pathway for dural sealants and fibrin glues in the U.S. As neurosurgeons and spine teams migrate toward precision platforms, demand rises for adjunctive products that are reliable, compatible with minimally invasive workflows, and deliver predictable watertight closure in constrained operative fields. A 2025 scientometric analysis published in Cureus reviewed the publication trends for dural sealants in spine surgery. It found that nearly 40% of research originates in the U.S., and recent research topics have shifted from “types of sealants” to “clinical outcomes, safety, efficacy, and workflow integration”.

Furthermore, an industry review of surgical robotics published by MPO Magazine in October 2025 described the field entering a “new phase” where platforms emphasize software-led differentiation, outpatient redesign and compatibility with adjunct devices. These data points demonstrate a growing intersection between advanced surgical platforms (robotics/IGS) and dural adjunct technologies, creating a substantive momentum for sealants and glues optimized for these environments. These factors are collectively contributing to the growth of market.

U.S. Dural Sealants And Fibrin Glues Market Report Segmentation

This report forecasts revenue growth at the country level and analyzes the latest industry trends in each sub-segments from 2024 to 2035. For this study, Grand View Research has segmented the U.S. dural sealants and fibrin glues market report based on CPT procedure codes and end use:
  • CPT Procedure Codes Outlook (Revenue, USD Unit, 2024 - 2035)
  • 61510 / 61512 - Craniotomy for supratentorial lesion removal
  • 61320 - 61323 - Craniectomy or craniotomy, decompressive (with or without duraplasty)
  • 61518- Craniotomy for infratentorial/posterior fossa lesion
  • 62140 / 62141- Cranioplasty or dural reconstruction
  • 63707- Repair of CSF leak, cranial or spinal, without laminectomy
  • 63709 - Repair of CSF leak or pseudomeningocele with laminectomy
  • 63710- Dural graft (spinal)
  • 63030 - Laminotomy/laminectomy (lumbar), decompression of nerve root
  • 63047 - Laminectomy, >1 vertebral segment, lumbar
  • 22612 / 22630 - Posterior spinal fusion with decompression
  • End Use Outlook (Revenue, USD Unit, 2024 - 2035)
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

125 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. CPT Procedure Codes
1.2.2. End Use
1.2.3. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. CPT Procedure Codes
2.2.2. End Use outlook
2.3. Competitive Insights
Chapter 3. U.S. Dural Sealants and Fibrin Glues Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising neurosurgical and spinal procedures
3.2.1.2. Focus on patient safety and reduced reoperations
3.2.1.3. Breakthrough biomaterials driving next-gen dural repair
3.2.2. Market Restraint Analysis
3.2.2.1. Unnecessary back surgeries limiting ethical utilization
3.2.2.2. Availability of alternative techniques
3.3. U.S. Dural Sealants and Fibrin Glues Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. U.S. Dural Sealants and Fibrin Glues Market: CPT Procedure Codes Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Dural Sealants and Fibrin Glues Market: CPT Procedure Codes Movement Analysis
4.3. U.S. Dural Sealants and Fibrin Glues Market by CPT Procedure Codes Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2024 to 2035 for the following
4.5. 61510 / 61512 - Craniotomy for Supratentorial Lesion Removal
4.5.1. 61510 / 61512 - Craniotomy for Supratentorial Lesion Removal Market Revenue Estimates and Forecasts, 2024 - 2035 (USD Million)
4.6. 61320 - 61323 - Craniectomy or Craniotomy, Decompressive (With or Without Duraplasty)
4.6.1. 61320 - 61323 - Craniectomy or Craniotomy, Decompressive (With or Without Duraplasty) Market Revenue Estimates and Forecasts, 2024 - 2035 (USD Million)
4.7. 61518- Craniotomy for Infratentorial/Posterior Fossa Lesion
4.7.1. 61518- Craniotomy for Infratentorial/Posterior Fossa Lesion Market Revenue Estimates and Forecasts, 2024 - 2035 (USD Million)
4.8. 62140 / 62141- Cranioplasty or Dural Reconstruction
4.8.1. 62140 / 62141- Cranioplasty or Dural Reconstruction Market Revenue Estimates and Forecasts, 2024 - 2035 (USD Million)
4.9. 63707- Repair of CSF Leak, Cranial or Spinal, Without Laminectomy
4.9.1. 63707- Repair of CSF Leak, Cranial or Spinal, Without Laminectomy Market Revenue Estimates and Forecasts, 2024 - 2035 (USD Million)
4.10. 63709 - Repair of CSF Leak or Pseudomeningocele with Laminectomy
4.10.1. 63709 - Repair of CSF Leak or Pseudomeningocele with Laminectomy Market Revenue Estimates and Forecasts, 2024 - 2035 (USD Million)
4.11. 63710- Dural Graft (Spinal)
4.11.1. 63710- Dural Graft (Spinal) Market Revenue Estimates and Forecasts, 2024 - 2035 (USD Million)
4.12. 63030 - Laminotomy/Laminectomy (Lumbar), Decompression of Nerve Root
4.12.1. 63030 - Laminotomy/Laminectomy (Lumbar), Decompression of Nerve Root Market Revenue Estimates and Forecasts, 2024 - 2035 (USD Million)
4.13. 63047 - Laminectomy, >1 Vertebral Segment, Lumbar
4.13.1. 63047 - Laminectomy, >1 Vertebral Segment, Lumbar Market Revenue Estimates and Forecasts, 2024 - 2035 (USD Million)
4.14. 22612 / 22630 - Posterior Spinal Fusion with Decompression
4.14.1. 22612 / 22630 - Posterior Spinal Fusion with Decompression Market Revenue Estimates and Forecasts, 2024 - 2035 (USD Million)
Chapter 5. U.S. Dural Sealants and Fibrin Glues Market: End Use Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. Dural Sealants and Fibrin Glues Market: End Use Movement Analysis
5.3. U.S. Dural Sealants and Fibrin Glues Market by End Use Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2024 to 2035 for the following
5.5. Hospitals
5.5.1. Hospitals Market Revenue Estimates and Forecasts, 2024 - 2035 (USD Million)
5.6. Ambulatory Surgical Centers
5.6.1. Ambulatory Surgical Centers Market Revenue Estimates and Forecasts, 2024 - 2035 (USD Million)
5.7. Specialty Clinics
5.7.1. Specialty Clinics Market Revenue Estimates and Forecasts, 2024 - 2035 (USD Million)
Chapter 6. Competitive Landscape
6.1. Market Participant Categorization
6.2. Key Company Profiles
6.2.1. Integra LifeSciences
6.2.1.1. Company overview
6.2.1.2. Financial performance
6.2.1.3. Product benchmarking
6.2.1.4. Strategic initiatives
6.2.2. Stryker
6.2.2.1. Company overview
6.2.2.2. Financial performance
6.2.2.3. Product benchmarking
6.2.2.4. Strategic initiatives
6.2.3. Baxter
6.2.3.1. Company overview
6.2.3.2. Financial performance
6.2.3.3. Product benchmarking
6.2.3.4. Strategic initiatives
6.2.4. Ethicon (J&J)
6.2.4.1. Company overview
6.2.4.2. Financial performance
6.2.4.3. Product benchmarking
6.2.4.4. Strategic initiatives
6.2.5. Takeda Pharmaceutical
6.2.5.1. Company overview
6.2.5.2. Financial performance
6.2.5.3. Product benchmarking
6.2.5.4. Strategic initiatives
6.2.6. B. Braun Medical
6.2.6.1. Company overview
6.2.6.2. Financial performance
6.2.6.3. Product benchmarking
6.2.6.4. Strategic initiatives
6.2.7. Cook Medical
6.2.7.1. Company overview
6.2.7.2. Financial performance
6.2.7.3. Product benchmarking
6.2.7.4. Strategic initiatives
6.2.8. Polyganics
6.2.8.1. Company overview
6.2.8.2. Financial performance
6.2.8.3. Product benchmarking
6.2.8.4. Strategic initiatives
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.